# Nuclide record nct06040099 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct06040099/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct06040099", "NCT06040099" ;
  schema:name "A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat"@en ;
  schema:alternateName "EMERALD-Y90"@en ;
  schema:description "A phase 2 trial of Durvalumab, Bevacizumab in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct06040099/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06040099> ;
  nuclide:status "active" ;
  nuclide:tag "ctgov-ingest" ;
  nuclide:phase "2" ;
  nuclide:related <https://nuclide.cc/isotopes/y-90/> ;
  nuclide:indications <https://nuclide.cc/indications/hcc/> ;
  nuclide:drugs <https://nuclide.cc/drugs/durvalumab/> ;
  nuclide:companies <https://nuclide.cc/companies/astrazeneca/> .